Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.
Immunocore Holdings plc (NASDAQ: IMCR) is a leading biotechnology company at the forefront of developing groundbreaking T cell receptor (TCR) bispecific immunotherapies. Leveraging its world-class TCR technology, Immunocore aims to harness the body's immune system to target and destroy diseased cells. The company's proprietary platform, known as ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer), is designed to treat a variety of serious conditions, including cancer, infectious diseases, and autoimmune disorders.
Based in the United Kingdom, Immunocore has a significant presence in the United States, where the majority of its revenue is generated. The company's most notable product, KIMMTRAK® (tebentafusp-tebn), is the first approved TCR therapy for metastatic uveal melanoma, available in the United States, European Union, Canada, Australia, and the United Kingdom.
In recent news, Immunocore has entered into a clinical trial collaboration with Bristol Myers Squibb to investigate IMC-F106C, an ImmTAC bispecific TCR candidate, in combination with nivolumab for treating advanced cutaneous melanoma. This Phase 3 trial aims to assess the efficacy and safety of this combination therapy.
Immunocore's robust pipeline includes several clinical-stage programs in oncology and infectious diseases. Notable developments include ongoing trials for IMC-I109V for Hepatitis B Virus (HBV) and advanced pre-clinical programs in autoimmune diseases. Additionally, the company is expanding its PRAME ImmTAC franchise with two new candidates, IMC-P115C and IMC-T119C, targeting solid tumors.
Financially, Immunocore has successfully transitioned from a research-focused organization to a revenue-generating entity. The company's collaborative efforts with partners like DELFI Diagnostics aim to enhance cancer therapy monitoring through innovative liquid biopsy assays.
Immunocore continues to pioneer in the field of immunotherapy, with a mission to deliver transformative treatments that radically improve patient outcomes.
Immunocore (NASDAQ: IMCR) reported Q4 2024 financial results with KIMMTRAK net sales of $84.1M and full-year sales of $310.0M. The company achieved 11 consecutive quarters of revenue growth and expanded to 14 new territories.
Q4 net loss was $23.8M ($0.47 per share) compared to $19.7M in Q4 2023. Full-year 2024 net loss was $51.1M ($1.02 per share) versus $55.3M in 2023. R&D expenses increased to $222.2M from $163.5M in 2023.
Key developments include:
- KIMMTRAK now approved in 39 countries and launched in 24
- First patient randomized in Phase 3 PRISM-MEL-301 trial
- Initiated Phase 1/2 trial of IMC-R117C for colorectal cancers
- Strong cash position of $820.4M as of December 31, 2024
- Repaid $50M Pharmakon loan in November 2024
Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025.
The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss the financial results and provide updates on its business and portfolio. The webcast will be accessible through the 'Events' section of Immunocore's website, with a replay available for a time afterward.
Immunocore Holdings (Nasdaq: IMCR) outlined its strategic priorities for 2025, focusing on expanding KIMMTRAK's global reach and advancing its clinical portfolio. The company is currently enrolling three Phase 3 trials across multiple melanoma indications, with initial data readouts expected in 2026.
Key priorities include building a melanoma franchise through additional launches and increased community penetration, with KIMMTRAK now available in 23 countries. The company is advancing multiple clinical trials, including Phase 1/2 trials with brenetafusp combinations in ovarian and lung cancer, and ongoing dose escalation studies.
The company plans to submit clinical trial applications for two autoimmune disease candidates: IMC-S118AI for Type 1 diabetes in 2025 and IMC-U120AI for atopic dermatitis in 2026. Preliminary unaudited cash position was approximately $820 million as of December 31, 2024.
Immunocore Holdings plc (Nasdaq: IMCR) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company, which specializes in developing transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, will deliver a presentation on Wednesday, January 15, 2025, at 8:15 a.m. PST.
The presentation will be accessible through a live webcast on the 'Events & Presentations' section of Immunocore's website under the 'Investors' tab. A replay of the presentation will be available for a time after the event.
Immunocore Holdings plc (Nasdaq: IMCR) has appointed Travis Coy as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. Coy transitions from his role as Non-Executive Director, which he held since September 2019, to become an Executive Officer.
Coy brings over 20 years of experience from Eli Lilly and Company, where he most recently served as Vice President, Head of Transactions and M&A, Corporate Business Development. His previous roles at Eli Lilly included leading business development for oncology and cardiometabolic diseases, financial leadership of the oncology business unit, Director of Investor Relations, and Director of Corporate Finance and Investment Banking.
The appointment leverages Coy's deep knowledge of Immunocore's operations and science, gained during his five-year tenure as a Non-Executive Director, to support the company's mission in delivering transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases.
Immunocore (IMCR) has initiated the Phase 1 trial of IMC-P115C, its first half-life extended ImmTAC candidate, with the first patient now dosed. IMC-P115C targets PRAME (PReferentially expressed Antigen in MElanoma) and shares the same CD3 effector and TCR specificity as brenetafusp, but is designed with an extended half-life to improve patient convenience through reduced treatment frequency.
The Phase 1 dose escalation trial will evaluate safety, pharmacokinetics, and clinical activity in HLA-A*02:01-positive patients with advanced cancers expressing PRAME. This marks Immunocore's sixth ImmTAC candidate to enter clinical trials, building upon their existing PRAME dataset from brenetafusp's Phase 1/2 trials.
Immunocore (IMCR) has initiated patient treatment in a Phase 1/2 trial for IMC-R117C, their fifth ImmTAC candidate, targeting PIWIL1 in colorectal and other gastrointestinal cancers. The trial will evaluate both monotherapy and combination treatments with standard care in HLA-A*02:01-positive patients with advanced solid tumors.
IMC-R117C represents the first immunotherapy program targeting PIWIL1, a cancer-testis antigen overexpressed in multiple malignancies, including colorectal cancer (CRC). The company estimates up to 20,000 colorectal cancer patients globally are positive for both PIWIL1 and HLA-A*02:01. This development addresses a significant unmet medical need, particularly in advanced colorectal cancer cases resistant to standard treatments.
Immunocore (NASDAQ: IMCR) and EORTC have initiated the first Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM), enrolling their first patient. The trial aims to evaluate if tebentafusp can prevent or delay relapse in high-risk uveal melanoma patients after primary treatment, compared to observation.
The open-label, international, multicenter trial will enroll 290 HLA-A*02:01-positive patients who have undergone surgery or radiotherapy. Participants will be randomized 1:1 to receive either tebentafusp for six months or observation. The study will assess overall survival, safety, tolerability, and explore ctDNA as a marker of residual disease.
Tebentafusp (KIMMTRAK®) is currently approved in 38 countries for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Immunocore (IMCR) announced that KIMMTRAK (tebentafusp) has been recommended for funding through England's National Health Service (NHS) by NICE. This recommendation overturns their initial negative decision from May 2023. KIMMTRAK is approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, marking the first treatment to improve survival for this rare form of melanoma. The therapy will be funded on the NHS in England starting December 2, 2024, representing Immunocore's 13th launch this year.
Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines, has announced its participation in two upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12, 2024, at 1:00 p.m. EST, and the Jefferies London Healthcare Conference on Wednesday, November 21, 2024, at 9:00 a.m. GMT.
Both presentations will be available via webcast on Immunocore's website in the 'Events & Presentations' section, with replays available for a time after the events.
FAQ
What is the current stock price of Immunocore Holdings Plc (IMCR)?
What is the market cap of Immunocore Holdings Plc (IMCR)?
What does Immunocore Holdings plc do?
What is the proprietary platform of Immunocore?
What is KIMMTRAK?
Where does Immunocore generate most of its revenue?
What recent collaboration has Immunocore entered into?
What are some of the clinical-stage programs Immunocore is working on?
What are PRAME ImmTAC candidates?
What is the mission of Immunocore?
How has Immunocore evolved financially?
What role does DELFI Diagnostics play in Immunocore's research?
